This study demonstrates that IL-18 in the RM1 tumor environment, achieved either by IL-18 gene-introduction or direct injection can slow the growth of both subcutaneous and orthotopic tumors in in vivo models, thus provides proof of concept that IL-18 has potential as an immunotherapeutic agent for prostate cancer. The gene discussed is IL18; the disease is prostate carcinoma.